CD8A and breast cancer: It was shown that among patients treated with paclitaxel, higher frequencies of naïve CD4+ or CD8+ T cells (CD45RA+CD95−CD27+CD28+) were associated with worse prognosis, as they correlated with shorter breast cancer specific survival (CD8+: 28.7 vs. 12.6 months, HR = 0.32 95% CI: 0.15–0.67, P = 0.0028; CD4+: 29.4 vs. 15.1 months, HR = 0.45 95% CI: 0.22–0.91, P = 0.027).